Chester County News and Community Website
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) appointed Chief Medical Officer Faisal Mehmud as chief executive officer of its UK subsidiary Antev Limited, effective Aug. 30, consolidating leadership as …
Medicus Puts Mehmud at Antev Helm as Drug Program Advances Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has received authorization from the Abu Dhabi Department of Health to begin a Phase 2a clinical trial of its investigational therapy Teverelix …
ICYMI: Medicus Pharma Wins UAE Trial Authorization for Endometriosis Study Read More PHILADELPHIA, PA — Medicus Pharma Ltd. received FDA clearance to begin a registrational Phase 2b trial of its SkinJect microneedle patch in patients with Gorlin Syndrome, advancing the treatment toward …
ICYMI: FDA Clears Medicus to Begin Gorlin Syndrome SkinJect Trial Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) received authorization from Abu Dhabi health regulators to proceed with a Phase 2a trial of Teverelix in women with symptomatic endometriosis, advancing …
Medicus Wins UAE Clearance for Genomics-Guided Drug Trial Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) received U.S. Food and Drug Administration authorization to begin a registrational Phase 2b study of its SkinJect treatment in patients with Gorlin …
FDA Clears Medicus to Start Gorlin Syndrome Drug Study Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) is moving toward activation of a redesigned Phase 2 Teverelix trial after receiving FDA feedback and central ethics approval, cutting planned enrollment …
ICYMI: Medicus Advances Leaner Teverelix Trial After FDA Review Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) plans to test its Teverelix drug candidate in about 126 patients after receiving FDA feedback and central ethics approval for a redesigned …
Medicus Cuts Planned Teverelix Trial Enrollment by Two-Thirds Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) has asked the U.S. Food and Drug Administration to grant Rare Pediatric Disease Designation for its experimental SkinJect therapy in patients with …
ICYMI: Medicus Seeks FDA Rare Disease Status for Skin Cancer Therapy Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has asked the U.S. Food and Drug Administration to grant Rare Pediatric Disease Designation for SkinJect, its experimental treatment for patients with …
Medicus Seeks FDA Rare Disease Status for Skin Cancer Therapy Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has submitted an application to health regulators in Abu Dhabi to begin a genomics-based Phase 2a study of its investigational drug Teverelix …
Medicus Seeks UAE Approval for Genomics-Based Endometriosis Trial Read More